Simon Fu

579 total citations
11 papers, 205 citations indexed

About

Simon Fu is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Simon Fu has authored 11 papers receiving a total of 205 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 8 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Simon Fu's work include Cancer Genomics and Diagnostics (8 papers), Renal cell carcinoma treatment (8 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Simon Fu is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Renal cell carcinoma treatment (8 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Simon Fu collaborates with scholars based in New Zealand, Canada and United States. Simon Fu's co-authors include Steven Yip, Evan W. Warner, Amanda Wong, Cameron Herberts, Alexander W. Wyatt, Toni K. Choueiri, Benoit Beuselinck, Kevin Beja, Daniel Khalaf and Matti Annala and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Simon Fu

10 papers receiving 204 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Fu New Zealand	6	176	99	96	62	25	11	205
Matthew Labriola United States	6	159 0.9×	82 0.8×	137 1.4×	72 1.2×	28 1.1×	23	238
Scott Barker United States	6	175 1.0×	72 0.7×	155 1.6×	57 0.9×	12 0.5×	19	259
Maddalena Donini Italy	8	112 0.6×	49 0.5×	64 0.7×	69 1.1×	45 1.8×	29	191
Ana Bolanos Canada	4	252 1.4×	61 0.6×	159 1.7×	38 0.6×	16 0.6×	5	286
M. Gross Goupil France	9	164 0.9×	63 0.6×	70 0.7×	98 1.6×	41 1.6×	26	213
J. Vandebroek Belgium	7	197 1.1×	76 0.8×	129 1.3×	54 0.9×	12 0.5×	12	265
Carlos Mayo United States	9	151 0.9×	41 0.4×	164 1.7×	75 1.2×	28 1.1×	16	254
Susann Stephan-Falkenau Germany	7	157 0.9×	66 0.7×	118 1.2×	65 1.0×	14 0.6×	11	224
Roberto Sánchez-Reyes Mexico	6	278 1.6×	98 1.0×	228 2.4×	118 1.9×	19 0.8×	8	368
H. Akamatsu Japan	4	279 1.6×	89 0.9×	211 2.2×	68 1.1×	19 0.8×	10	314

Countries citing papers authored by Simon Fu

Since Specialization

Citations

This map shows the geographic impact of Simon Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Fu more than expected).

Fields of papers citing papers by Simon Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Fu. The network helps show where Simon Fu may publish in the future.

Co-authorship network of co-authors of Simon Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Fu. A scholar is included among the top collaborators of Simon Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Fu. Simon Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Chahoud, Jad, Bradley A. McGregor, Òscar Reig, et al.. (2025). Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.. Journal of Clinical Oncology. 43(16_suppl). 4515–4515.

Chacón, Matías, Sergio Bracarda, Marco Maruzzo, et al.. (2022). Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology. 40(16_suppl). TPS4621–TPS4621. 2 indexed citations

Annala, Matti, Sinja Taavitsainen, Daniel Khalaf, et al.. (2021). Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research. 27(16). 4610–4623. 52 indexed citations

Warner, Evan W., Cameron Herberts, Simon Fu, et al.. (2021). BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research. 27(6). 1650–1662. 52 indexed citations

Stukalin, Igor, J. Connor Wells, Jeffrey Graham, et al.. (2019). Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Current Oncology. 26(2). 175–179. 22 indexed citations

Fu, Simon, et al.. (2018). Real world experience of docetaxel in elderly patients with advanced prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 313–313. 1 indexed citations

Stukalin, Igor, J. Connor Wells, Jeffrey Graham, et al.. (2018). Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology. 36(6_suppl). 615–615. 2 indexed citations

Yip, Steven, J. Connor Wells, Raphael Brandão Moreira, et al.. (2018). Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 124(18). 3677–3683. 55 indexed citations

Yip, Steven, Frede Donskov, Anna Paola Fraccon, et al.. (2017). Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). PubMed. 1(1). 41–47. 10 indexed citations

10.

Yip, Steven, Raphael Brandão Moreira, Alex H.C. Wong, et al.. (2017). Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.. Journal of Clinical Oncology. 35(6_suppl). 492–492. 8 indexed citations

11.

Yip, Steven, Frede Donskov, Anna Paola Fraccon, et al.. (2016). Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology. 34(15_suppl). 4570–4570. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact